Opto Circuits (I) Ltd. subsidiary EuroCor GmbH presents very convincing clinical results from the DIOR® DEBUIT Trial

Paris|Mumbai May 28, 2010. Dr.Peter Stella, Principal Investigator for the DEBUIT Multi-center Clinical Study, on May 26th 2010 presented late breaking results involving the EuroCor Drug-Eluting-Balloon Catheter (DEB) at the EuroPCR Conference in Paris, France.

The results were presented as part or late-breaking trail results selected annually by the EuroPCR. The study compared the effectiveness of the EuroCor DIOR® DEB device in combination with a bare metal stent (BMS) vs. other treatment options involving drug-eluting stents and uncoated balloon catheters.

The study results as presented clearly show very strong and significant clinical advantages provided by the DIOR® DEB in bifurcated lesions with significantly reduced rates of binary restenosis as well as lower rates for MACE, TLR and TVR. The randomized study adds to the growing set of clinical data that documents significant and lasting clinical advantages delivered by the use of the EuroCor DIOR® Drug coated Dilatation Catheter.

"Having launched the first CE-marked Drug-eluting Balloon Catheter over two years ago, Opto's subsidiary EuroCor is a clear leader and innovator in this novel device space", says Vinod Ramnani, Chairman and Managing Director of Opto Circuits (I)." We are very pleased to hear that this fully randomized multi-center clinical study has validated our vision and belief in the DIOR® DEB device", he continued.

The DIOR® DEB is used to treat the narrowing and calcifications of coronary arteries and is specifically designed to improve outcomes in In-stent-restenosis (ISR), bifurcated lesions and small vessels.
Used independently or in combination with a Bare-Metal Stent, the DIOR® DEB delivers a low-risk and cost-effective alternative to the well known Drug-eluting stents (DES) in use for several years now.

A further advantage of the DIOR® device is that the regiment of blood-thinners required after the procedure is reduced to 90 days in comparison to 12 months or more that is required after stenting with a Drug-eluting stent. Further information is available

About Opto Circuits (India) Ltd.
Opto Circuits (India) Ltd. (OCI) (BSE Code: 532391; NSE Symbol: OPTOCIRCUI) is a 100 percent EOU and a leading manufacturer of healthcare equipment in India. The product profile includes digital thermometers, sensors, pulse oximeters, patient monitoring systems, stents, catheters and other innovative products. In 2001, OCI acquired 60 per cent stake in Advanced Micronic Devices (AMDL) to market and distribute its products in India. Mediaid came into existence with the acquisition of the patient monitoring division of Palco Labs, US, in end-2003 and it now directly markets OCI's products in the US. OCI acquired Eurocor GmbH in 2006. EuroCor manufactures Cardiac Stents of various types, including Drug Eluting Coronary stents. In April 2007, OCI ventured into new product segments - Urology, Gastroenterology, Gynecology and Orthopedics after acquiring Devon Innovations Private Limited (Bangalore) and Ormed Medical Technology Limited (Chennai). OCI completed the acquisition of US based Criticare Systems, Inc. in April 2008. Criticare designs, manufactures, and markets leading edge patient monitoring systems, vital signs monitors and gas benches for a wide range of hospitals and alternate health care environments throughout the world.
Visit us at www.optoindia.com; www.eurocor.de;

For further details on this release, please contact:

Neha Goenka
Adfactors PR, Mumbai
+91 22 22813565

Harini Iyengar
Adfactors PR, Bengaluru
+91 80 51133060/62/64

OPTO CIRCUITS (INDIA) LTD.